Encouraging lawmakers to pass legislation and promote policies that positively affect rheumatologists, rheumatology care teams and those living with rheumatic disease is one of the most impactful ways the ACR advances its mission. The role of advocacy has never been more critical than in recent months, when we have seen an unprecedented number of executive…
As of the close of the second quarter of CY2025, RheumPAC has raised $51,865 from 141 ACR members.
My first exposure to pediatric rheumatology came during my adult rheumatology fellowship, when pediatric rotations were part of our curriculum. This experience brought home for me the many differences between childhood and adult rheumatic diseases and the important role pediatric rheumatologists play in patient outcomes. This role has long been appreciated by the ACR/ARP, where…
Incoming Arthritis & Rheumatology Editor-in-Chief Dr. S. Louis Bridges Jr., MD, PhD, discusses his path to rheumatology and outlines his vision for the journal.
The ARP Nominations & Appointments Committee plays a pivotal role in overseeing the nominations process, ensuring the election and appointment of qualified leaders and volunteers who reflect the diverse membership of ARP. Together with the ACR’s Marketing & Communications Department, we kick off the 2025 term by promoting the annual Call for Volunteers and identifying…
When speaking to ACR and ARP members, people are always interested in hearing about the most recent news coming out of the ACR, specifically in areas of interest to them and their patients. It was these discussions that prompted me to make enhancing connections and communications between the ACR and its members one of my…
In visits to Congress members and staff, more than 120 ACR/ARP members and patients urged action to improve patient access to quality treatment. The meetings included discussions about the importance of research funding, ensuring adequate Medicare reimbursement, protecting Medicaid, and making PBMs more transparent and accountable. It’s not too late to amplify their message.
The rescindment of the Richardson Waiver in late February suggests that the HHS may move toward rulemaking without providing public notice and comment procedures.
The nominations of Jay Bhattacharya, MD, PhD, as director of the National Institutes of Health and Martin Makary, MD, MPH, for commissioner of the Food & Drug Administration have the potential to significantly impact federally funded healthcare research, federal responses to public health emergencies and federal regulation of drugs and medical devices.
This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.